Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT06080204 |
Other study ID # |
ChanghaiH-PP12 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 2008 |
Est. completion date |
April 2020 |
Study information
Verified date |
September 2023 |
Source |
Changhai Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks
evidence-based data and is controversial. Real-world data were clustered to validate whether
the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence
risk G2 pNET patients.
Description:
Adjuvant therapy for pNETs was proposed as an unmet clinical need by the European
Neuroendocrine Tumor Society Group in 2016.1The Clinical Practice Guidelines for pNETs in
China recommended initiation of clinical trials to investigate the role of adjuvant therapy
for patients with a high-risk of recurrence. To address this unmet clinical need, the
investigators initiated this real-world study. The aim of the current study was to assess the
impact of octreotide LAR as an adjuvant therapy in reducing recurrence and prolonging
survival in Chinese non-metastatic pNETs patients at risk for recurrence.